JP2018517667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517667A5 JP2018517667A5 JP2017552909A JP2017552909A JP2018517667A5 JP 2018517667 A5 JP2018517667 A5 JP 2018517667A5 JP 2017552909 A JP2017552909 A JP 2017552909A JP 2017552909 A JP2017552909 A JP 2017552909A JP 2018517667 A5 JP2018517667 A5 JP 2018517667A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- composition
- antibody
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 78
- 239000012634 fragment Substances 0.000 claims description 58
- 239000000427 antigen Substances 0.000 claims description 56
- 108091007433 antigens Proteins 0.000 claims description 56
- 102000036639 antigens Human genes 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 47
- 210000004072 lung Anatomy 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 2
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 239000000168 bronchodilator agent Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000003754 fetus Anatomy 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 230000001788 irregular Effects 0.000 claims description 2
- 230000004199 lung function Effects 0.000 claims description 2
- 230000032646 lung growth Effects 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 230000035764 nutrition Effects 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 238000002640 oxygen therapy Methods 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 201000004193 respiratory failure Diseases 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 230000003519 ventilatory effect Effects 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims 4
- 230000003442 weekly effect Effects 0.000 claims 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144247P | 2015-04-07 | 2015-04-07 | |
| US62/144,247 | 2015-04-07 | ||
| PCT/US2016/026436 WO2016164579A1 (en) | 2015-04-07 | 2016-04-07 | Anti-flt-1 antibodies in treating bronchopulmonary dysplasia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191516A Division JP2021014473A (ja) | 2015-04-07 | 2020-11-18 | 気管支肺異形成症を治療する抗ｆｌｔ−１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517667A JP2018517667A (ja) | 2018-07-05 |
| JP2018517667A5 true JP2018517667A5 (enExample) | 2019-05-16 |
| JP6797825B2 JP6797825B2 (ja) | 2020-12-09 |
Family
ID=55795198
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552909A Active JP6797825B2 (ja) | 2015-04-07 | 2016-04-07 | 気管支肺異形成症を治療する抗ｆｌｔ−１抗体 |
| JP2020191516A Pending JP2021014473A (ja) | 2015-04-07 | 2020-11-18 | 気管支肺異形成症を治療する抗ｆｌｔ−１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191516A Pending JP2021014473A (ja) | 2015-04-07 | 2020-11-18 | 気管支肺異形成症を治療する抗ｆｌｔ−１抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10711065B2 (enExample) |
| EP (2) | EP3280735B1 (enExample) |
| JP (2) | JP6797825B2 (enExample) |
| CN (1) | CN107683143A (enExample) |
| AU (3) | AU2016246738B2 (enExample) |
| CA (1) | CA2981961A1 (enExample) |
| HK (1) | HK1249913A1 (enExample) |
| MA (1) | MA41900A (enExample) |
| MX (1) | MX2017012831A (enExample) |
| WO (1) | WO2016164579A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3768299A1 (en) * | 2018-03-22 | 2021-01-27 | The Children's Medical Center Corporation | Methods and compositions relating to lung repair |
| WO2019246521A1 (en) | 2018-06-22 | 2019-12-26 | Shire Human Genetic Therapies, Inc. | Anti-flt-1 antibodies in treating bronchopulmonary dysplasia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7335362B2 (en) | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
| US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| KR101215701B1 (ko) * | 2002-07-19 | 2012-12-26 | 베스 이스라엘 데코니스 메디칼 센터 | 자간전증 또는 자간의 진단 및 치료 방법 |
| CN102397542B (zh) | 2004-11-18 | 2014-05-07 | 英克隆有限责任公司 | 抗血管内皮生长因子受体-1的抗体 |
| US20060153835A1 (en) | 2005-01-12 | 2006-07-13 | Smith Henry J | Treatment of pre-eclampsia in pregnant women using targeted apheresis |
| US8349325B2 (en) * | 2008-12-23 | 2013-01-08 | Abbott Laboratories | Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making |
| WO2012109282A2 (en) * | 2011-02-07 | 2012-08-16 | Agamin Pharmaceuticals, Llc | Methods and systems for treating or preventing pregnancy-related hypertensive disorders |
| CA2898998C (en) | 2013-01-28 | 2023-02-14 | Regents Of The University Of Minnesota | Anti-flt-1 antibodies in treating duchenne muscular dystrophy |
| TW201517916A (zh) | 2013-03-15 | 2015-05-16 | Lilly Co Eli | Ｖｅｇｆｒ１抗體之治療用途 |
-
2016
- 2016-04-07 US US15/565,009 patent/US10711065B2/en active Active
- 2016-04-07 CN CN201680032821.0A patent/CN107683143A/zh active Pending
- 2016-04-07 JP JP2017552909A patent/JP6797825B2/ja active Active
- 2016-04-07 HK HK18109380.9A patent/HK1249913A1/zh unknown
- 2016-04-07 MA MA041900A patent/MA41900A/fr unknown
- 2016-04-07 EP EP16717527.2A patent/EP3280735B1/en active Active
- 2016-04-07 AU AU2016246738A patent/AU2016246738B2/en active Active
- 2016-04-07 EP EP22156748.0A patent/EP4063390A1/en active Pending
- 2016-04-07 MX MX2017012831A patent/MX2017012831A/es unknown
- 2016-04-07 CA CA2981961A patent/CA2981961A1/en active Pending
- 2016-04-07 WO PCT/US2016/026436 patent/WO2016164579A1/en not_active Ceased
-
2020
- 2020-06-05 US US16/893,999 patent/US20210130475A1/en not_active Abandoned
- 2020-11-18 JP JP2020191516A patent/JP2021014473A/ja active Pending
-
2022
- 2022-03-15 AU AU2022201781A patent/AU2022201781B2/en active Active
-
2024
- 2024-10-01 AU AU2024227035A patent/AU2024227035A1/en active Pending